ClinicalTrials.gg
RecruitingNCT07223242TEXPEFUpdated Oct 31, 2025

Tailored Exercise Training Study Among Adults With HFpEF

A Phase 2/3 interventional study of Moderate-intensity continuous training (MCT) and Resistance training in HFpEF - Heart Failure With Preserved Ejection Fraction and Diabetic Cardiomyopathies, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-31.

Sponsored by University of Texas Southwestern Medical Center · Phase 2/3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2025, registered Oct 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers.

This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.

Read the detailed description

Heart failure (HF) portends substantial morbidity, mortality, and health care costs in the United States and the prevalence of heart failure with preserved ejection fraction (HFpEF) relative to HF with reduced ejection fraction (HFrEF) has been increasing. HFpEF is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. It is now recognized as a systemic, multi-organ, geriatric syndrome, with exercise intolerance (EI) and functional impairment as the key clinical manifestations. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers.

This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare the effects of four different lifestyle interventions on exercise capacity.

The study will be carried out in two phases. In Phase I, 120 participants will undergo three months of home-based moderate-intensity continuous training (MCT), using tailored exercise videos on a mobile or tablet. Participants will also have weekly virtual meetings with a coach to discuss their progress. This will be followed by 3 months of no intervention, to assess the effects of detraining.

In Phase II (at the 6-month mark), 100 participants will be randomized to one of four extended training strategies for 3 months -(i) MCT alone; (ii) MCT plus resistance training; (iii) MCT plus weight loss, or (iv) MCT plus resistance training and weight loss.

The co-primary outcomes are (1) peak VO2, and (2) short physical performance battery score. In addition, participants will undergo CT chest/abdomen/pelvis at 3 months and 6 months to assess change in skeletal muscle composition with MCT

02

Conditions studied

  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • Diabetic Cardiomyopathies

Keywords

  • Diabetic cardiomyopathy
  • Remote exercise training
  • Weight loss
  • Rehab
03

In context

Diabetic Cardiomyopathies

30 studies on the registry are indexed under Diabetic Cardiomyopathies; 9 are open to participants now.

This study's planned enrollment of 120 is above the median of 81 across 15 interventional studies indexed under Diabetic Cardiomyopathies.

Browse Diabetic Cardiomyopathies studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age>= 18 yrs
  2. (Left Ventricular Ejection Fraction) >= 50%
  3. History of HFpEF or at risk of HFpEF

    1. HFpEF diagnosis based on:- -HF hospitalization within 12 months-

      • NT-proBNP >360 pg/mL
    2. Risk of HFpEF based on:-

      • >2 risk factors (h/o diabetes, hypertension, obesity, physical inactivity by self-report)
  4. SPPB \< 10 or VO2\<60th percentile
  5. >=28 (for randomization in phase II)
  6. Able to use cell phone and mobile application

Exclusion criteria

Exclusion Criteria:

  1. Hospitalization 1 month prior to baseline visit
  2. History of recurrent falls
  3. (Estimated Glomerular Filtration Rate) \<20ml/min/1.73m
  4. Active changes in HF therapies over 2 weeks prior to baseline visit
  5. Inability participate in exercise training therapy
  6. Inability to perform CPET (Cardiopulmonary Exercise Testing) testing
  7. Severe left side valvular heart disease
  8. End stage pulmonary disease, requiring continuous supplemental oxygen
  9. Major surgery within 3 months of screening or major elective surgery during the duration of the study.
  10. Unstable weight defined by >5% change in body weight in last 30 days before first study visit.
  11. Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Moderate-intensity continuous training (MCT)

    Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

    Behavioral: Moderate-intensity continuous training (MCT)

  • Experimental
    Moderate-intensity continuous training + weight loss

    Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + initiation/intensification of pharmacological weight loss

    Behavioral: Moderate-intensity continuous training (MCT) · Drug: Weight loss

  • Experimental
    Moderate-intensity continuous training + resistance training

    Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos

    Behavioral: Moderate-intensity continuous training (MCT) · Behavioral: Resistance training

  • Experimental
    Moderate-intensity continuous training + resistance training + weight loss

    Tailored moderate-intensity exercise training videos with weekly virtual meetings with a coach + tailored resistance training videos + initiation/intensification of pharmacological weight loss

    Behavioral: Moderate-intensity continuous training (MCT) · Behavioral: Resistance training · Drug: Weight loss

Interventions

  • BehavioralModerate-intensity continuous training (MCT)

    Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach

  • BehavioralResistance training

    Resistance training videos assigned to patient

  • DrugWeight loss

    Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Peak Exercise Oxygen Uptake (VO2peak)

    VO2peak indexed to body weight (mL/kg/min) will be the co-primary outcome for the trial. VO2peak is a gold-standard measure of aerobic exercise capacity and will be measured by maximal exercise test using a previously established ergometer protocol

    Time frame: Baseline, 3months, 6months, and 9months

  2. Short Physical Performance Battery (SPPB)

    SPPB will be a co-primary outcome for the trial. Score ranges from 0 to 12, with 0 indicating the worst performance and 12 indicating the best.

    Time frame: Baseline, 3months, 6months, and 9months

Secondary outcomes

  1. Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12)

    Health-related quality of life will be assessed using the KCCQ-12 questionnaire. This is a self-administered questionnaire that assesses a patient's perception of their heart failure with regard to the psychological, physical, and socioeconomic aspects of life. Scores range from 0 to 100, where 0 indicates the worst possible health status and 100 indicates the best.

    Time frame: Baseline, 3months, 6months, and 9months

  2. 6 Minute Walk Distance (6MWD)

    6MWD is a simple and well-validated measure of submaximal exercise capacity and does not require any exercise equipment or advanced training for technicians

    Time frame: Baseline, 3months, 6months, and 9months

  3. General Quality of Life - EQ-5D-5L

    Change in general health-related quality of life assessed using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) instrument. The EQ-5D-5L uses a descriptive system to measure health-related quality of life across five key dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on five levels of severity-ranging from no problems (Level 1) to extreme problems or inability to function (Level 5). A respondent's answers generate a five-digit health state profile that reflects their unique combination of responses (e.g., 12345), representing one of 3,125 possible health states. This descriptive system enables consistent and standardized assessment of an individual's health status.

    Time frame: Baseline, 3months, 6months, and 9months

  4. Thirty Second Chair Test

    The 30-second chair stand test measures lower-body strength and endurance by counting how many times a person can stand up from a chair and sit down within 30 seconds.

    Time frame: Baseline, 3months, 6months, and 9months

  5. Fried Frailty Phenotype

    The Fried frailty phenotype defines frailty based on five criteria-unintentional weight loss, exhaustion, weakness, slow walking speed, and low physical activity. Each criterion met adds one point to the total score. The Fried Frailty scale has a score range of 0 to 5. A score of 0 means the person is robust or not frail, a score of 1 or 2 indicates pre-frailty (intermediate risk), and a score of 3 or more means the person is considered frail.

    Time frame: Baseline, 3months, 6months, and 9months

  6. Resting cardiac output

    Assess with echocardiography to measure stroke volume and heart rate during rest

    Time frame: Baseline, 3months, 6months, and 9months

  7. Exercise cardiac output

    Assess with echocardiography to measure stroke volume and heart rate responses with graded physical stress.

    Time frame: Baseline, 3months, 6months, and 9months

  8. Intramyocellular fat

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans will be used to measure the radiodensity of muscle tissue, quantified in Hounsfield Units (HU). Skeletal muscle tissue is assigned a range of HU values (-29 to +150). Higher fat content lowers the overall muscle density, resulting in lower HU values

    Time frame: Baseline, 3months, 6months, and 9months

  9. Intermuscular Adipose Tissue (IMAT)

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans quantify intermuscular adipose tissue (IMAT) using the Hounsfield unit (HU) scale, where IMAT is classified as fat density within a range of -250 to -30 HU. The area of fat deposits is then quantified in square centimeters (cm\^2)

    Time frame: Baseline, 3months, 6months, and 9months

  10. Subcutaneous adiposity deposits

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans quantify fat deposits using the Hounsfield unit (HU) scale, where fat is defined as a density within a range of -250 to -30 HU. The area of fat deposits is then quantified in square centimeters (cm\^2)

    Time frame: Baseline, 3months, 6months, and 9months

  11. Visceral Adiposity Deposits

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans quantify fat deposits using the Hounsfield unit (HU) scale, where fat is defined as a density within a range of -250 to -30 HU. The area of fat deposits is then quantified in square centimeters (cm\^2)

    Time frame: Baseline, 3months, 6months, and 9months

  12. Pericardial Adiposity Deposits

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans quantify fat deposits using the Hounsfield unit (HU) scale, where fat is defined as a density within a range of -250 to -30 HU. The area of fat deposits is then quantified in square centimeters (cm\^2)

    Time frame: Baseline, 3months, 6months, and 9months

  13. Lower Body Adiposity Deposits

    Assessed with non-contrast CT scans of the chest, abdomen, and pelvis. These scans quantify fat deposits using the Hounsfield unit (HU) scale, where fat is defined as a density within a range of -250 to -30 HU. The area of fat deposits is then quantified in square centimeters (cm\^2)

    Time frame: Baseline, 3months, 6months, and 9months

  14. E/e': Ratio of early mitral inflow velocity (E) to early diastolic mitral annular velocity (e')

    Exercise echocardiography to measure E/e' ratio to assess left ventricular filling pressures at rest and during graded physical stress

    Time frame: Baseline, 3months, 6months, and 9months

  15. Left atrial reservoir strain

    Assessed using echocardiography at rest and during graded physical stress

    Time frame: Baseline, 3months, 6months, and 9months

  16. Left ventricular global longitudinal strain (LV GLS)

    Assessed using echocardiography at rest and during graded physical stress

    Time frame: Baseline, 3months, 6months, and 9months

  17. GAD 7 score

    Change in anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

    Time frame: Baseline, 3months, 6months, and 9months

  18. PHQ 9 score

    This is a self-administered questionnaire that assesses the severity of depressive symptoms. The PHQ-9 (Patient Health Questionnaire-9) ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, 3months, 6months, and 9months

  19. NT-proBNP

    Serum level of NT-proBNP (N-terminal pro-brain natriuretic peptide), a biomarker that reflects cardiac stress.

    Time frame: Baseline, 3months, 6months, and 9months

  20. High-sensitivity troponin I

    Serum high-sensitivity troponin I reflects ongoing low-grade myocardial injury and is a marker of disease severity and prognosis in chronic heart failure.

    Time frame: Baseline, 3months, 6months, and 9months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 31, 2025
StartActual
Feb 18, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07223242
Responsible party
Ambarish Pandey (Associate Professor of Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Oct 31, 2025
Start date
Feb 18, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion